Wu‐Chou Su

37.0k citations
364 papers · 17.0k indexed · 8 hit papers · h-index 60

Impact in

  • Oncology top 0.1%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Lung Cancer Research Studies 55
    • Colorectal Cancer Treatments and Studies 40
    • Cancer Immunotherapy and Biomarkers 27
    • Lung Cancer Treatments and Mutations 137
    • Lung Cancer Diagnosis and Treatment 33
    • Gastric Cancer Management and Outcomes 21

Wu‐Chou Su

354 papers receiving 16.8k citations

Hit Papers

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC 2023 · 263 citations
263199620262006201650010001.5k2.0k

Peers

Wu‐Chou Su
Comparison fields: 5 of 176
  • Oncology 9.0k
  • Pulmonary and Respiratory Medicine 8.6k
  • Cancer Research 3.0k
  • Hepatology 762
  • Molecular Biology 6.5k
Replace Sun Young Rha with:
Sun Young Rha South Korea
Luis Paz‐Ares Spain
Chandra P. Belani United States
Ramaswamy Govindan United States
Kenneth J. O’Byrne Australia
Benjamin Solomon Australia
Giampaolo Tortora Italy
Ezra E.W. Cohen United States
Julian R. Molina United States
Juan W. Valle United Kingdom
Wu‐Chou Su relative to Sun Young Rha South Korea Sun Young Rha's profile →
Citations per field
00.5×1.5×1.8×
Sun Young Rha · 1×
Citations per year

Countries citing papers authored by Wu‐Chou Su

Since Specialization
Citations

This map shows the geographic impact of Wu‐Chou Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wu‐Chou Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wu‐Chou Su more than expected).

Fields of papers citing papers by Wu‐Chou Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wu‐Chou Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wu‐Chou Su. The network helps show where Wu‐Chou Su may publish in the future.

Co-authors

The 25 scholars most cited alongside Wu‐Chou Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wu‐Chou Su Line = papers co-authored together Wu‐Chou Su links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20251
3 20243
4 20241
5 20241
6 20235
7 20234
8 202222
9
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON
Hit paper breakdown →
202295
10 20226
11 202158
12 202031
13 201815
14 201718
15 201713
16 201644
17 201512
18 20143
19
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Hit paper breakdown →
20132461
20 201126

About Wu‐Chou Su

Wu‐Chou Su is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hepatology and Molecular Biology, having authored 364 papers that have together received 17.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (137 papers), Lung Cancer Research Studies (55 papers), Colorectal Cancer Treatments and Studies (40 papers), Lung Cancer Diagnosis and Treatment (33 papers), Cancer Immunotherapy and Biomarkers (27 papers), Cancer Genomics and Diagnostics (23 papers), Gastric Cancer Management and Outcomes (21 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (20 papers). The work is most often cited by research in Oncology (9.0k citations), Pulmonary and Respiratory Medicine (8.6k citations), Cancer Research (3.0k citations), Hepatology (762 citations) and Molecular Biology (6.5k citations). Wu‐Chou Su has collaborated with scholars based in Taiwan, United States and South Korea. Frequent co-authors include James Chih‐Hsin Yang, Mehdi Shahidi, Helen H.W. Chen, Lecia V. Sequist, Vera Hirsh, Harrison Echols, Tony Mok, Sang-We Kim, Ki Hyeong Lee and Terufumi Kato. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026